HalozymeHALO
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 373
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
185% more call options, than puts
Call options by funds: $36.9M | Put options by funds: $12.9M
5% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 77
8% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 180
3% less funds holding
Funds holding: 501 [Q3] → 486 (-15) [Q4]
4.19% less ownership
Funds ownership: 100.25% [Q3] → 96.06% (-4.19%) [Q4]
20% less capital invested
Capital invested by funds: $7.27B [Q3] → $5.85B (-$1.42B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
8%
downside
Avg. target
$64
11%
upside
High target
$75
30%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Benchmark Robert Wasserman 60% 1-year accuracy 30 / 50 met price target | 30%upside $75 | Buy Reiterated | 20 Feb 2025 |
HC Wainwright & Co. Mitchell Kapoor 32% 1-year accuracy 57 / 176 met price target | 25%upside $72 | Buy Maintained | 19 Feb 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target | 1%downside $57 | Equal-Weight Maintained | 13 Jan 2025 |
Piper Sandler Joseph Catanzaro 41% 1-year accuracy 14 / 34 met price target | 8%downside $53 | Neutral Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 17 articles about HALO published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
2 days ago
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Neutral
Seeking Alpha
3 days ago
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
3 days ago
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
3 days ago
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago.
Neutral
PRNewsWire
3 days ago
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.26 1 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.23 1 , Both Exceeding Guidance Reiterating 2025 Financial Guidance Ranges for Total Revenue of $1,150 - 1,225 million, Representing YOY Growth of 13% - 21%, Adjusted EBITDA of $755 - $805 million, Representing YOY Growth of 19% - 27% and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YOY Growth of 17% - 26%1 SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, provided an update on its recent corporate activities and reiterated its 2025 financial guidance. "I am excited to announce that the significant growth we achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology.
Positive
Zacks Investment Research
4 days ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
4 days ago
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
Positive
Zacks Investment Research
1 week ago
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Positive
Zacks Investment Research
1 week ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Charts implemented using Lightweight Charts™